| Literature DB >> 28662027 |
Gaotai Cai1, Bohong Chen1,2, Zhen Li1, Wei Wei1, Ping Wang1, Wenqi Dong1.
Abstract
Liver fibrosis, a common pathological process of chronic liver diseases, is the final stage of liver dysfunction that has severely deleterious impact on human health. Cytoglobin was first discovered in 2001 by proteomic analysis in rat stellate cells and was reported to play an important role in controlling tissue fibrosis. However, the mechanism by which cytoglobin inhibits or reverses the progression of fibrosis remains unclear. The present study examines the effect of recombinant human cytoblobin (rhCygb) in a rat model of liver fibrosis. Proteomic approaches were employed to identify differentially expressed proteins in the fibrosis model. Optimized conditions for two-dimensional gel electrophoresis were developed to provide improved protein detection and separation. A total of 43 spots were obtained and, through the use of matrix-assisted laser desorption ionization time-of-flight mass spectrometry, 30 differentially expressed proteins were identified. Gene ontology term annotation and KEGG pathway analysis allowed us to explore the function of the represented proteins. Based on these results, we provide a theory of the molecular mechanism related to rhCygb reversion of fibrosis and which will assist in the identification of biomarkers in patient serum to improve early diagnosis of liver fibrosis.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28662027 PMCID: PMC5490966 DOI: 10.1371/journal.pone.0177968
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1HE and Sirius red staining of liver biopsy samples among the different groups.
A, B and C: the HE staining of liver biopsy of the control group, fibrosis model group and rhCygb treatment group, respectively. D, E and F: the Sirius red staining of liver biopsy samples of the control group, fibrosis model group and rhCygb treatment group, respectively.
Anti-hepatic fibrosis effect of rhCygb in CCl4-induced liver fibrosis model rats( ± s, n = 30).
| Groups | ALT(U/L) | AST(U/L) | LN(ng/ml) | HA(ng/ml) | Col III(ng/ml) | Col IV(ng/ml) |
|---|---|---|---|---|---|---|
| Control | 35.52±4.3 | 37.58±6.35 | 26.45±6.35 | 97.33±15.26 | 14.3±3.5 | 26.35±5.23 |
| Model | 521.46±98.77 | 622.33±98.77 | 103.75±12.44 | 378.95±48.23 | 78.23±14.6 | 58.78±7.89 |
| rhCygb | 47.25±7.6 | 55.26±7.6 | 28.52±7.6 | 108.56±25.68 | 17.2±3.3 | 28.24±5.66 |
a Compared with control group P<0.01;
c Compared with model group P<0.01
Fig 2Effect after treatment with different kits on 2-DE of serum proteome.
A: Using the Albumin/IgG removal kit, the proteins did not separate well. The main high-abundance proteins were α2-HS glycoprotein, albumin, transferrin, IgA, haptoglobin, Ig heavy chain, α1-antitrypsin, α1-macroglobulin and Ig light chain. B: Use of the ProteinMiner Protein Enrichment Kit resulted in proteins that were separated by a large degree.
Fig 32-DE analysis of serum samples and the corresponding differentially expressed protein spots.
A: Control group, B: Firbosis model group, C: rhCygb treatment group, D: Fifteen representative differentially expressed protein spots were magnified from three pairs of serum samples. The spots on the left side of the figure were up-regulated in fibrosis model group, while spots on the right were down-regulated in the fibrosis model group. Using a pH3-10, 17cm nonliner IPG Strip and 12.5%SDS-PAGE, we identified 43 different proteins on the gels.
Identification of 30 proteins differentially expressed among the control, fibrosis model, and rhCygb groups.
| ID | Protein name | Swiss-prot Accession | MW | PI | Protein Score | rhCygb | Protein function |
|---|---|---|---|---|---|---|---|
| 1 | 60 kDa heat shock protein, mitochondrial | P63039 | 610088.45 | 5.96 | 269 | ↓ | Positive regulation of inflammatory response; Responseto hypoxia |
| 2 | Argininosuccinate lyase | P20673 | 51643.24 | 6.20 | 112 | ↓ | Cellular response to hypoxia; Cellular response to tumor necrosis factor; Diaphragm development; Arginine biosynthetic proces process |
| 5 | FGFR1 oncogene partner 2 homolog | Q6TA25 | 25048.81 | 5.27 | 62.8 | ↓ | Response to wounding; Wound healing; Accelerates the collagen gel contraction in vitro |
| 6 | Clusterin | P05371 | 51969.54 | 5.47 | 65.8 | ↓ | Response to oxidative stress; Response to wounding; Positive regulation of NF-kappaB transcription factor activity |
| 7 | RGD1311188 protein | B1WC62 | 40258.69 | 9.79 | 62.9 | ↓ | Metal ion binding; Nucleic acid binding |
| 9 | LRRGT00008 | Q6TXJ1 | 183308.21 | 10.44 | 65.6 | ↓ | RNA binding |
| 12 | Bileacid-CoA: amino acid N-acyltransferase | Q63276 | 46777.17 | 7.46 | 101 | ↓ | Organ regeneration; Liver development; Bile acid metabolism |
| 13 | Pink1 | D3Z9M9 | 27675.61 | 11.4 | 71.2 | ↓ | Cellular response to toxic substance; Positive regulation of I-kappa B kinase/NF-kappaB signaling; Response to stress |
| 15 | Proteasome subunit alpha type-6 | P60901 | 27837.98 | 6.74 | 72.5 | ↓ | Positive regulation of NF-kappaB transcription factor activity; Ubiquitin-dependent protein catabolic process |
| 16 | Proteasome subunit beta type-6 | P28073 | 25515.54 | 4.61 | 147 | ↓ | Proteolysis involved in cellular protein catabolic process |
| 17 | Protein Smarca5 | F1LNL2 | 15813.06 | 9.65 | 63.1 | ↓ | ATP-binding; DNA binding binding |
| 20 | Glyceraldehyde-3-phosphate dehydrogenase | P04797 | 122992.34 | 8.4 | 96.4 | ↓ | Microtubule cytoskeleton organization |
| 23 | Apolipoprotein E | P02650 | 103861.79 | 4.93 | 64.2 | ↑ | Negative regulation of inflammatory response; A ligand for the LDL (apo B/E) receptor |
| 25 | Itih4 | Q5EBC0 | 35788.35 | 6.11 | 68.3 | ↑ | Acute-phase response; Hyaluronan metabolic process |
| 26 | NmrA-like family domain-containing protein 1 | P86172 | 34638.68 | 6.8 | 159 | ↑ | Redox sensor protein; Reduces the production of nitric oxide |
| 27 | Ig kappa chain C region, B allele | P01835 | 26017.67 | 5.26 | 78 | ↑ | Fc-gamma receptor signaling pathway involved in phagocytosis; Innate immune response |
| 29 | Ig lambda-2 chain C region | P20767 | 11481.67 | 5.8 | 70.5 | ↑ | Immunoglobulin domain |
| 30 | Peroxiredoxin-2 | P35704 | 21941.13 | 5.28 | 160 | ↑ | Removal of superoxide radicals; Response to oxidative stress; Peroxidase activity |
| 31 | Galectin-9 | P97840 | 36692.36 | 8.66 | 137 | ↑ | Ion transport |
| 32 | Galectin-5 | P47967 | 16414.11 | 6.66 | 91.7 | ↑ | May function in erythrocyte differentiation |
| 33 | Galectin-5 | P47967 | 16414.11 | 6.66 | 81.6 | ↑ | May function in erythrocyte differentiation |
| 34 | Brefeldin A-inhibited guanine nucleotide-exchange protein 2 | Q7TSU1 | 204296.96 | 6.48 | 68.1 | ↑ | Golgi to plasma membrane transport; Intracellular signal transduction |
| 36 | Hbb-b1 hemoglobin, beta adult major chain | Q62669 | 16069.28 | 8.51 | 137 | ↑ | Oxygen transport from the lung to the various peripheral tissues |
| 37 | Beta-2-microglo-bulin | P07151 | 13825.17 | 8.23 | 65.7 | ↑ | Immune response; Response to drug |
| 38 | Hemoglobin subunit alpha-1/2 | P01946 | 15489.83 | 8.14 | 373 | ↑ | Oxygen transport from the lung to the various peripheral tissues |
| 39 | Ifi44l | M0R4J5 | 90125.05 | 8.97 | 69.5 | ↑ | Immune response |
| 40 | Hemoglobin subunit alpha-1/2 | P01946 | 15489.83 | 8.14 | 241 | ↑ | Oxygen transport from the lung to the various peripheral tissues |
| 41 | C4-2 complement component 4, gene 2 | Q6MG90 | 193602.9 | 7.04 | 255 | ↑ | Inflammatory response; Complement activation |
| 42 | Complement C4 | P08649 | 193638.91 | 7.34 | 202 | ↑ | Inflammatory response; Complement activation; Innate immune response |
| 43 | Complement C4 | P08649 | 193638.91 | 7.34 | 95.9 | ↑ | Inflammatory response; Complement activation; Innate immune response |
Fig 4Analysis of Protein—Protein Interaction Network.
Fig 5Distribution of all serum altered proteins into different functional and categories.
a: response to oxidative stress; b: regulation of response to stimulus; c: regulation of immune system process; d: response to inflammatory; e: response to wounding; f: anti-apoptotic process; g: cellular macromolecule catabolic process; h: positive regulation of NF-kB transcription factor activity; i: extracellular region; j: cytosol; k: endosome; l: mitochondrion; m: plasome lipoprotein particle; n: ATP binding; o: ubiquitin protein ligase binding; p: antioxidant activity.
GO analysis of the corresponding differentially expressed proteins.
| Protein function categories | Up-regulated in fibrosis model group | Up-regulated in rhCygb treatment group |
|---|---|---|
| Response to oxidative stress | Pink1; 60 kDa heat shock protein, mitochondrial | Apolipoprotein E; Peroxiredoxin-2; Hbb-b1 hemoglobin, beta adult major chain; Hemoglobin subunit alpha-1/2 |
| Response to stimulus | Argininosuccinate lyase; FGFR1 oncogene partner 2 homolog | Peroxiredoxin-2; Beta-2-microglo-bulin; C4-2 complement component 4, gene 2 |
| Regulation of immune system process | Complement C4; Beta-2-microglobulin; Ig lambda-2 chain c region; Ig kappa chain c region, B allele; Ifi441 | |
| Response to inflammtion | 60 kDa heat shock protein, mitochondrial | Apolipoprotein E; C4-2 complement component 4, gene 2; Complement C4 |
| Oxygen transpotation | Hemoglobin subunit alpha-1/2; Hbb-b1 hemoglobin, beta adult major chain; Galectin-5; Galectin-9 | |
| NF-kB signaling | Proteasome subunit beta type-6; Clusterin; Pink1 |